Counterweight Ventures LLC Has $710,000 Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Counterweight Ventures LLC lifted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 591.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 93,384 shares of the biotechnology company’s stock after purchasing an additional 79,884 shares during the period. Counterweight Ventures LLC’s holdings in BioCryst Pharmaceuticals were worth $710,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares during the last quarter. Xponance Inc. raised its holdings in BioCryst Pharmaceuticals by 13.1% in the second quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 1,505 shares during the period. Creative Planning raised its holdings in BioCryst Pharmaceuticals by 5.9% in the third quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock worth $375,000 after purchasing an additional 2,734 shares during the period. CWM LLC boosted its position in shares of BioCryst Pharmaceuticals by 200.0% during the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,772 shares in the last quarter. Finally, Diversified Trust Co grew its holdings in shares of BioCryst Pharmaceuticals by 18.0% in the 2nd quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company’s stock valued at $153,000 after buying an additional 3,774 shares during the period. Institutional investors own 85.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on BCRX shares. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. JMP Securities boosted their price objective on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 6th. Barclays raised their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $14.67.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $7.15 on Tuesday. The firm has a fifty day simple moving average of $7.69 and a 200 day simple moving average of $7.18. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. During the same quarter in the prior year, the business earned ($0.19) EPS. The business’s revenue was up 35.1% compared to the same quarter last year. Equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.